Home/Pipeline/NOX4 Inhibitor (GLX7013114)

NOX4 Inhibitor (GLX7013114)

Diabetic Retinopathy

PreclinicalActive

Key Facts

Indication

Diabetic Retinopathy

Phase

Preclinical

Status

Active

Company

Glucox Biotech

About Glucox Biotech

Glucox Biotech is a preclinical-stage, private biotech firm pioneering the development of selective NOX4 inhibitors for metabolic and vascular diseases. The company's scientific foundation is built on targeting NADPH oxidase 4 (NOX4), an enzyme implicated in oxidative stress pathways driving diabetic complications, stroke, and kidney injury. Its lead candidate, GLX7013114, has been featured in peer-reviewed research for diabetic retinopathy, validating its approach. Glucox operates as a research-focused entity seeking academic and industry partnerships to advance its pipeline toward clinical development.

View full company profile

Therapeutic Areas

Metabolic Disease Ophthalmology Nephrology Cardiovascular Neurology

Other Diabetic Retinopathy Drugs

Drug	Company	Phase	Status
Undisclosed Program (DR)	Cloudbreak Pharmaceutical	Pre-clinical / Clinical	In pipeline; uses ADS Platform
PER-001	Perfuse Therapeutics	Phase 2	Active
jCell (RPCs)	jCyte	Preclinical	Active
LumineticsCore	Digital Diagnostics	Approved	Active
Diabetic Retinopathy Program	Lxbio Pharmaceuticals	Pre-clinical	Active
Undisclosed	Hillhurst Biopharmaceuticals	Preclinical	Active
NBP-14 and derivatives	Neuro Bio	Research	Active
Vasculogenic Cell Therapy	Vascugen	Pre-clinical	Active
Danegaptide	Breye Therapeutics	Phase 2	Active
OcuRetina	Oculotix	Phase 2	Active
YH14618	Yuhan	Phase 2	Active